ROCHESTER, Minn. — The molecular makeup of brain tumors can be used to sort patients with gliomas into five categories, each with different clinical features and outcomes, researchers at Mayo Clinic and the University of California San Francisco have shown. The finding could change the methods that physicians rely on to determine prognosis and treatment options. Previously, they relied on how patients’ tumors look under the microscope. The study is published online in the New England Journal of Medicine.
According to a research team at the Duke University Preston Robert Tisch Brain Tumor Center, a low dosage of a modified poliovirus therapy shows promising results for patients with a glioblastoma or GBM, a highly malignant brain tumor. Dosage findings of the first 20 patients in the Phase I trial were presented at the 2015 American Society of Clinical Oncology annual meeting in Chicago.